reticulum (ER) as a precursor protein harboring a propeptide that prevents the receptor from binding ligands prematurely. Sortilin is then converted to its mature form in the trans-Golgi network (TGN) by furin-mediated proteolytic cleavage, 8 at which point it can bind select ligands, one of which is apo B 100 (apolipoprotein B 100 ). 2, 4, 9 Sortilin participates in trafficking cargo (1) to constitutive secretory vesicles; (2) to the endosomal compartment, from which associated proteins can further travel to the plasma membrane, lysosomes, or other locations; and (3) to secretory granules. A minor fraction of sortilin is also present at the plasma membrane where it acts both as a signaling and endocytosis receptor. 10 Apo B 100 is the principal protein component of VLDL and one of its products, LDL, and is among the strongest risk factors for the development of heart disease. 11 In contrast to many other secreted hepatic proteins whose secretion is regulated by synthesis, apo B 100 secretion is primarily regulated by its degradation rate, which occurs both during VLDL assembly and maturation. 12, 13 We and others have discovered several apo B 100 degradation pathways in hepatocytes, including proteasomedependent ER-associated degradation and a post-ER presecretory proteolysis that in some examples uses macroautophagy. 14 Macroautophagy (hereafter referred to as autophagy) was initially characterized as a protein catabolic pathway to recycle amino acids during nutrient deprivation 15 ; however, the contribution of autophagy to the regulation of lipid metabolism has increasingly gained importance. Besides the regulation of VLDL secretion through the degradation of apo B 100 , 14 different forms of selective autophagy regulate intracellular lipid breakdown directly through lipophagy or indirectly through degradation of 
Novelty and Significance
What Is Known?
• Genome-wide association studies identified a genetic variant present in the SORT1 gene promoter associated with lower LDL-C (low-density lipoprotein cholesterol), less cardiovascular disease, and increased expression of the encoded protein sortilin 1, or sortilin, in the liver.
• Subsequent studies in mice showed that hepatic sortilin overexpression reduced the production of apo B 100 (apolipoprotein B 100 ) and VLDL (very-low-density lipoprotein; precursor of LDL), by diversion from the secretory pathway.
• In studies in vitro, sortilin-bound apoB and its increased expression resulted in lysosomal degradation of apoB and VLDL (apoB/VLDL).
What New Information Does This Article Contribute?
• We show that when sortilin is overexpressed in hepatic cells, it induces an unconventional form of lysosomal targeting of apoB/VLDL, in which sortilin and apoB/VLDL traffic to the endosomal compartment in vesicles that fuse with autophagosomes to form amphisomes, which merge with lysosomes.
• Sortilin is also a novel regulator of autophagy; when overexpressed, sortilin increases the degradative capacity, or flux, of this pathway.
• Studies of the effects of sortilin overexpression on apoB/VLDL production in vivo were consistent with the in vitro studies. Overall, our studies suggest that the cell biological fate of apoB/VLDL in humans with sortilin overexpression and diversion of apoB/VLDL from the secretory pathway is degradation through a prelysosomal, autophagy-dependent intermediate process.
A polymorphism in the SORT1 gene is associated by genomewide association studies with lower LDL-C and decreased cardiovascular disease risk. Given these desirable associations, the underlying mechanisms are of considerable interest. There is increased mRNA and protein (sortilin) encoded by SORT1 in the livers of individuals with the polymorphism. Consistent with this finding, when sortilin was overexpressed in hepatic cells or mice, the secretion of apoB/VLDL was decreased. Thus, we explored the cell biological fate of apoB/VLDL diverted from secretion by sortilin. Sortilin sorts cargo from the trans-Golgi network to lysosomes (and the plasma membrane), and we hypothesized that the effects of sortilin overexpression on apoB/VLDL secretion represented conventional targeting to lysosomal degradation. Instead, we surprisingly found that the route is indirect and intersects with autophagy. Vesicles that contain sortilin and apoB/VLDL leave the secretory pathway and fuse with autophagic vacuoles, forming unusual structures called amphisomes. These, in turn, fuse with lysosomes. Although sortilin amplifies this autophagic degradation, blocking this unique pathway does not increase apoB/VLDL secretion, demonstrating that regulation of secretion resides with the activity of sortilin and not of autophagy. The results provide mechanistic insight into the apo B 100 degradation that results from sortilin-induced diversion of nascent VLDL from the secretion pathway. This degradation is an unusual example of the utilization of amphisomes, a rarely sighted autophagic intermediate, in the degradation process of apoB and nascent VLDL.
other lipid droplet components 16, 17 and control the rate of lipid synthesis through degradation of lipogenic enzymes. 18, 19 We and others have demonstrated a major effect of sortilin on the secretion of apo B 100 -containing lipoproteins. 2, 4, 5, 9 Specifically, overexpression of SORT1 in mouse liver to mimic the increased hepatic expression found in minor versus major allele homozygote individuals 2 reduced apo B 100 production in vivo. In cultured hepatic cells, sortilin overexpression similarly reduced apo B 100 secretion by promoting its trafficking to lysosomes, where it was presumably degraded. The specific route through which apo B 100 was delivered to the lysosome is unknown, though it has been assumed to be an example of the conventional direct pathway, in which vesicles bud from the TGN, traffic to the endosomal compartment, and fuse with lysosomes. Given the aforementioned role of autophagy in apo B 100 degradation, we hypothesized an unconventional, indirect route. Through a series of in vitro and in vivo studies, we now demonstrate that sortilin can route apo B 100 from the secretory pathway to the lysosome through an autophagic intermediate known as the amphisome, which results from the fusion of an endosome and an autophagosome. These findings provide novel mechanistic insights into the cellular basis for the clinical effects of SORT1 overexpression in the liver and illuminate special features of sortilin-mediated degradation of apo B 100 by the autophagic pathway.
Methods
The authors declare that all supporting data are available within the article (and its Online Data Supplement). Detailed Methods section is included in the Online Data Supplement. To confirm that increased SORT1 expression reduces apo B 100 secretion, as anticipated from our previous studies, 2, 4 we compared the secreted and intracellular levels of apo B 100 in McA cells overexpressing sortilin (McA-sortilin) or GFP (green fluorescent protein; McA-GFP, control) that were steady-state radiolabeled for 4 hours with 23 S-met/cys. Consistent with previous data, McA-sortilin cells showed a significant reduction in apo B 100 secretion, intracellular apo B 100 , and total apo B 100 ( Figure 1A ).
Results

Increased Sortilin Expression
To determine if autophagy is involved in the sortilin-mediated reduction in apo B 100 recovery, we performed pulse-chase studies in autophagy-sufficient and autophagy-deficient cells.
McA cells were transiently transfected with siRNA to Atg7, which is essential for autophagosome formation and autophagy 24 or a control siRNA. Twenty-four hours later, the cells were transfected with a plasmid expressing either myc-tagged human sortilin (wild type) or sortilin in which the furin recognition site is mutated, precluding propeptide cleavage and subsequent ligand binding (inactive sortilin). 8 The efficacy of the Atg7 siRNA was validated by observing lower ATG7 protein levels and a reduction in autophagosome maturation as indicated by a decrease in the phosphatidylethanolamine-conjugated form of the autophagosome membrane protein LC3 (microtubule-associated protein light chain 1A/1B-light-chain 3, LC3-II; Figure 1B ).
As shown in Figure 1C , McA cells overexpressing wildtype sortilin showed decreased apo B 100 recovery (ie, greater levels of protein degradation) when compared with cells transfected with the plasmid encoding the inactive cleavagedeficient sortilin species. Notably, this effect was abrogated by Atg7 knockdown. We also noted that ATG7-deficient McA cells showed a higher relative recovery of apo B 100 (ie, less degradation), indicating that autophagy contributes to basal degradation of apo B 100 , as recently observed (Guo et al, unpublished observations; the % attributable to autophagy was ≈40% and to ERassociated degradation, ≈50%). The increased level of apo B 100 in ATG7-deficient cells was attributable to the accumulation of apo B 100 intracellularly (Online Figure IA and IB), consistent with increased sortilin expression diverting more apo B 100 from the secretory pathway to a compartment from which it could no longer be secreted even when its degradation was inhibited. In additional pulse-chase studies (Online Figure II) , by using combinations of ATG7 siRNA and the proteasome inhibitor MG132, we were able to determine that the overall contribution of autophagy to apo B 100 degradation is similar to that of ERassociated degradation (Online Figure IIA Sortilin is known to bind a variety of ligands and promote their lysosomal degradation, 10 including proBDNF (pro-brainderived neurotrophic factor). 25 To determine if autophagy is a general degradation pathway for sortilin ligands, we cotransfected into ATG7-deficient or control McA cells plasmids expressing wild type or the inactive sortilin species along with a plasmid encoding proBDNF, which contained a human influenza HA (hemagglutinin) tag (proBDNF-HA). We then performed pulse-chase experiments to measure proBDNF recovery. Similar to the effects observed on apo B 100 , proBDNF recovery was also reduced in cells expressing wild-type sortilin relative to cells expressing the inactive sortilin species. Importantly, this effect was maintained in ATG7-deficient cells, indicating that sortilin does not require the autophagy pathway to deliver proBDNF to the lysosome ( Figure 1D ). Notably, in both experiments, there was no significant change in albumin relative recovery, suggesting that sortilin does not globally reduce protein secretion but exhibits ligand specificity ( Figure 1E ).
To independently investigate the requirement for autophagy in apo B 100 degradation when sortilin is overexpressed, we also studied the effects of the autophagy inhibitor 3-methyladenine (3-MA) 26 (Online Figure IV) . First, we observed that in cells in which sortilin was not overexpressed, 3-MA increased the intracellular accumulation of apo B 100 , but not its secretion. In the sortilin-overexpressing cells, 3-MA, as in the McA cells treated with ATG7 siRNA (Figure 1 ), the induction of apo B 100 degradation was prevented. Besides confirming a role for autophagy of apo B 100 in sortilin-overexpressing cells, the data show that, in general, when autophagy is inhibited, the rescued apo B 100 remains in the cell, apparently unavailable for secretion.
Previously published work demonstrated sortilin to be a bona fide cell surface LDL receptor whose overexpression and deficiency in cultured cells and mice are associated with increased and decreased LDL uptake and lysosomal degradation, respectively. 4 We also showed that the LDL receptor mediates the reuptake and lysosomal degradation of newly secreted apo B 100 lipoproteins. 27 To ensure that the apo B 100 degradation we observed in this study was not attributable to sortilin-mediated reuptake and subsequent delivery to lysosomes, we performed steady-state metabolic labeling experiments in the presence of either BSA or unlabeled LDL, which would compete with the newly synthesized radiolabeled apo B 100 lipoproteins for binding extracellular sortilin preventing the reuptake of newly secreted apo B 100 (Online Figure VA) , but not of other proteins, such as albumin (Online Figure  VB) . As shown in Online Figure When cells reached subconfluence (80%-90%), they were washed with PBS, and amino acid starved for 1 h before being subjected to steady-state metabolic labeling using a mixture of [ 35 S]-methionine and cysteine. After 4 h, cells were harvested and apo B 100 was immunoprecipitated, separated by SDS-PAGE, and bands quantified using a phosphorimager. The graphical data are displayed as the relative differences in secreted apo B 100 (left), intracellular apo B 100 (middle), and total (cell+medium), right apo B 100 between the cells transfected with GFP (set to 100%) vs sortilin. B-E, McA hepatic cells stably expressing human apo B 100 were transfected with Atg7 siRNA or with scrambled siRNA for 24 h. Then, cells were transfected with either a plasmid containing the full-length myc-tagged human sortilin (wild-type Sortilin, pcDNA3.1-hSORT1-myc) or a dominant-negative sortilin (Inactive Sortilin; pcDNA3.1-hPro-Sortilin) generated by mutation of the furin recognition site, which prevents sortilin binding to apo B 100 . B, Western blot for ATG7, LC3-I (microtubule-associated protein light chain 1A/1B-light-chain 3), and LC3-II levels 48 h after siRNA incubation. Tubulin was used as internal control. C, Pulse-chase results showing the recoveries of apo B 100 at the end vs beginning of the chase period, with Inactive Sortilin, Control siRNA set to 100%. D, Relative recovery of proBDNF (pro-brain-derived neurotrophic factor)-HA from McA hepatic cells transfected with Atg7 siRNA or with scrambled siRNA for 24 h. Before the pulse-chase study, an expression plasmid for proBDNF-HA (hemagglutinin) was cotransfected with an expression plasmid for either wild-type or inactive sortilin for 24 h. E, Relative recovery of albumin. Numeric data represent the means±SEM. *P<0.05 vs Control siRNA; #P<0.05 vs Atg7 siRNA using 2-tailed Student t test. The experiments were performed in triplicate. February 16, 2018 led to decreased recovery of radiolabeled apo B 100 with no change in the recovery of endogenously labeled albumin (Online Figure Vd ). These data demonstrate that the effect of sortilin on apo B 100 degradation is independent of its role as a cell surface LDL receptor.
Effects of Autophagy and Sortilin Overexpression on VLDL Production In Vivo
Our previous work suggested that increased sortilin expression reduced plasma LDL-C levels by promoting the presecretory lysosomal degradation of apo B 100 . 4 However, we did not establish whether sortilin chaperoned apo B 100 directly to the lysosome or whether sortilin functioned through an indirect pathway for lysosomal delivery. 2, 4 Our studies in McA cells raised the possibility that sortilin does not directly promote apo B 100 degradation, but in fact relies on an intact autophagy pathway. We therefore studied the effects of sortilin overexpression on apo B 100 metabolism in mice in which hepatic autophagy was either active or inactive.
In contrast to human liver, which produces only apo B 100 , mouse liver produces apo B 100 and apo B 48 , which is because of hepatic expression of the apob mRNA editing enzyme (Apobec1); in humans, Apobec1 is expressed only in the small intestine. 28, 29 To create a more humanized mouse model for our in vivo studies, we generated hepatic autophagy-sufficient and autophagy-deficient mice on an Apobec1 −/− , apo B 100 -only background. 30 Thus, Apobec1
−/− mice were crossed with mice with a floxed allele of the essential autophagy factor ATG5, Atg5 f/f mice. 31 This led to the creation of an Apobec1 −/− Atg5 f/f mouse. By treating these mice with a combination of an adeno-associated vectors (AAV) encoding Cre Recombinase (Cre) and either GFP (control) or sortilin-encoding AAV, we produced animals with acute hepatic sufficiency/deficiency of autophagy and normal/increased sortilin expression. We chose somatic gene deletion in contrast to constitutive deletion to avoid artifacts from the chronic sequelae of autophagy deficiency. Moreover, we chose to increase sortilin expression rather than developing a knockout animal because of its clinical relevance in human subjects. 2 Immunoblot and histological analyses performed 2 weeks after AAV injection confirmed the efficacy of the GFP and SORT1 vectors at achieving homogeneous gene overexpression (Figure 2A and 2B). The efficacy of AAV. Cre in blocking Atg5 expression was also confirmed by Western blot analysis ( Figure 2A ). Notably, ATG5 protein levels were dramatically reduced in Apobec1 −/− Atg5 f/f but not in Apobec1 −/− mice. In addition, Apobec1 −/− Atg5 f/f mice showed an accumulation of the unlipidated form of LC3 (LC3-I). As a consequence, mice overexpressing hepatic sortilin had significantly reduced VLDL-triglyceride and apo B 100 secretion rates when compared with mice overexpressing GFP. Notably, with autophagy deficiency, there was no increase over control where triglyceride or apo B 100 secretion was examined ( Figure 2C and 2D), consistent with the results in vitro (Online Figures IA, IB, and IV); that is, apo B 100 /VLDL diverted by sortilin overexpression does not seem to re-enter the secretory pathway to a significant extent when autophagy is inhibited ( Figure 2C and 2D).
Sortilin Associates With Autophagic Vesicles
Previous work showed that the interaction between sortilin and apo B 100 was stabilized in the presence of bafilomycin, 32 a vacuolar HC-ATPase [V-ATPase] inhibitor that alkalinizes the lysosome, thereby blocking substrate degradation. 33 This finding, together with the results shown above that autophagy is required for the in vitro and in vivo effects of sortilin on apo B 100 /VLDL secretion, prompted us to consider that the interaction between sortilin and apo B 100 is also autophagy dependent. To test this hypothesis, McA cells stably expressing sortilin (McA-sortilin) were treated with DMSO (control), bafilomycin, or 3-MA, and after a 3-hour incubation, intracellular proteins were cross-linked and sortilin was immunoprecipitated to capture the interaction between sortilin and apo B 100 . Western blot analyses of total cell homogenates showed that apo B 100 and sortilin levels were unaffected by the treatments ( Figure 3A) ; however, in cells treated with bafilomycin, there was increased recovery of apo B 100 after sortilin immunoprecipitation, consistent with previous observations. 32 In contrast, treatment with 3-MA, which prevents autophagosome formation, 26 reduced sortilin interaction with apo B 100 . Neither apo B 100 nor sortilin was detected in IgG control samples ( Figure 3B ).
Next, we used confocal microscopy to determine the relative localization of sortilin, apoB (predominately apo B 100 , but also some apo B 48 34 ), and LC3 (an integral component of autophagosomes) in McA/sortilin-expressing cells pretreated with bafilomycin. As shown in Figure 3C , we found that the 3 proteins colocalized. We next used ultrastructural analysis of immunogold staining to confirm the presence of sortilin and apoB in autophagic vacuoles, which are double-membrane vesicles representing either autophagosomes or amphisomes.
McA-sortilin cells were again treated with bafilomycin for 3 hours, and antibodies were used to detect sortilin or apoB. In this case, both proteins resided in the lumen of double-membrane vesicles of variable sizes and shapes ( Figure 3D ). We also simultaneously immunodetected sortilin and apoB using 2 gold-labeled secondary antibodies with different particle sizes (18 nm antichicken [apoB], 5 nm anti-rabbit [sortilin]). As shown in Figure 3E , double-stained images additionally revealed both apoB and sortilin in the same double-membrane structures ( Figure 3E ).
Although McA cells are enriched in apo B 100 as a consequence of stable expression of the human protein, some apo B 48 is still made because of persistent Apobec1 expression. To confirm that the data generated in the McA cells reflect the subcellular localization of apo B 100 and not apo B 48 , and to further validate our data in a more humanized model, we generated primary hepatocytes from the livers of Apobec1 −/− mice overexpressing sortilin through AAV-mediated transduction. We then treated these cells for 3 hours with vinblastine to prevent autophagosome-lysosome fusion and to inhibit autophagy. 35 Using the coimmunodetection protocol described above, we again observed sortilin and apo B 100 colocalization inside autophagic vacuoles ( Figure 3F ).
Sortilin Colocalizes With Endosome and Amphisome, but Not Phagophore, Markers
Autophagy begins with the formation of a double membrane (phagophore) that sequesters cytosolic material as it seals into a double membrane (autophagosome). Autophagosomes then fuse with lysosomes, which provide the hydrolases required for cargo degradation. However, a fraction of cellular autophagosomes can instead fuse first with endosomes or endosomederived vesicles to generate amphisomes, which then fuse with lysosomes to complete cargo degradation. 23 The finding that 3-MA treatment decreases the association between sortilin and apo B 100 ( Figure 3B ) suggests that sortilin and apo B 100 interaction is dependent on the formation of autophagosomes. Hence, we aimed to determine more precisely at which step sortilin is incorporated into an autophagic vesicle. To this end, we performed colocalization studies with different organelle markers, and, in agreement with previous reports, 4 indirect immunofluorescence microscopy showed sortilin colocalization with the TGN marker giantin and the early endosome marker EEA1 (early endosome antigen 1). Importantly, sortilin also colocalized with the late endosome/lysosome marker LAMP1 (late endosome and lysosomal marker lysosome-associated protein 1), as well as with the recycling endosome marker Rab11 ( Figure 4A and 4C), which functions in amphisome formation. 23 To further characterize the timing of sortilin colocalization with autophagy-related structures and to determine whether sortilin is incorporated into autophagosomes versus preautophagosomes (phagophores), we transiently transfected McA-sortilin cells with plasmids encoding ]-methionine and cysteine were precipitated using trichloroacetic acid, and these data were used to normalize the triglyceride and apo B 100 secretion rates. Numeric data represent the mean±SEM of 5 to 6 animals per group. *P<0.05; Student t test. February 16, 2018 EGFP-tagged ATG5 or ATG14L, proteins present at the limiting membrane (phagophore) during autophagosome formation and that dissociate during autophagosome maturation. 36 Confocal microscopy revealed that the degree of colocalization between sortilin and tagged ATG5 or ATG14L was significantly lower than that between sortilin and TGN or endosome markers. Similarly, sortilin colocalized at a greatly reduced level with the endogenous phagophore marker ATG16L ( Figure 4B and 4C) . We next determined the degree of colocalization between sortilin and STX17 (syntaxin 17), a protein only present in fully formed, mature autophagosomes. 37 In this case, a high degree of colocalization was evident ( Figure 4B and 4C). These data suggest that sortilin becomes incorporated into the autophagosome after it is fully formed, presumably via fusion of an endosome in which it resides with an autophagosome, thereby generating an amphisome.
To confirm that sortilin is present in amphisomes, which have both autophagosome and endosome markers, 38 we incubated McA-sortilin cells with exogenous Alexa 568-labeled transferrin (a marker of the endosomal compartment) for 10 minutes and performed colocalization experiments. Confocal microscopy revealed that the autophagosome marker LC3 colocalized with exogenous transferrin and with sortilin C, McA-sortilin cells were treated with bafilomycin, fixed, and permeabilized to detect the presence of LC3 (microtubule-associated protein light chain 1A/1B-light-chain 3; green), sortilin (red), and apoB (blue) using confocal microscopy. Individual images are represented in grayscale. Insets show magnified areas with colocalization, indicated by the white arrowheads. White bar, 10 μmol/L. D, McA-sortilin cells exposed to bafilomycin were subjected to immuno-electron microscopy for sortilin (left) and apoB (right), as shown by immunogold labeling. Insets show magnified areas where sortilin and apoB colocalize within double-membrane (ie, autophagic) vacuoles. These structures are indicated with black arrowheads. Black bar; 500 nm. E, Rabbit-anti-sortilin antibody was detected using protein A conjugated to a 5-nm gold particle, whereas chicken-anti apoB antibody was detected using a secondary antibody conjugated to a 16-nm gold particle in McA-sortilin cells treated with bafilomycin. F, Sortilin and apo B 100 were detected in hepatocytes isolated from apob mRNA editing enzyme (Apobec1 −/− ) mice treated with the adeno-associated vectors (AAV)-Sortilin expression vector. Once isolated, cells were exposed to vinblastine (50 μmol/L) for 3 h. Black bar; 100 nm. Numeric data represent the means±SEM. *P<0.05 vs vehicle-treated cells by 2-tailed Student t test. A.U. indicates arbitrary units.
( Figure 4D ). These results were confirmed and extended by colocalizing the endosome marker EEA1 with sortilin and LC3, supporting our conclusion that sortilin is present in the amphisome.
To further test the involvement of an amphisomal intermediate in sortilin-mediated apo B 100 degradation, we treated sortilin-overexpressing McA cells and appropriate GFP-overexpressing control cells with l-asparagine, a specific inhibitor of amphisome-lysosome fusion. 38 We hypothesized that if sortilin facilitated apo B 100 trafficking to the lysosome through an amphisome intermediate, disrupting this fusion event would decrease sortilin-mediated apo B 100 degradation. Indeed, we observed that l-asparagine increased the relative recovery of apo B 100 in both sets of cells, but a greater effect was observed in sortilin-overexpressing cells ( Figure 4E ). In contrast, l-asparagine had no effect on albumin recovery in either cell line ( Figure 4F ).
Sortilin and Apo B 100 Are Enriched in Autophagic Vacuoles and Colocalize With Amphisome Markers in Mouse Liver
To demonstrate sortilin-dependent autophagic degradation of apo B 100 in vivo, we injected Apobec1 −/− mice with AAVSortilin or AAV-GFP (control) and quantitated the amount of apo B 100 in hepatic autophagic vacuoles. We hypothesized that increased SORT1 expression would consequently increase the autophagic vacuole localization of apo B 100 . Two weeks after AAV injection, mice were fasted overnight, and 3 hours before euthanasia, they were injected with vinblastine to increase the recovery of autophagic vacuoles. 35 Fraction purity was confirmed by Western blot analysis of organellespecific markers in each subcellular fraction ( Figure 5A ; Online Figure VIA) , as previously described. 35 As expected, LC3-II was enriched in the autophagosomal/lysosomal fractions. The conjugated protein was also more abundant in autophagic vacuoles because degradation had not yet occurred in this compartment, as indicated by the low level of mature cathepsin D in this fraction.
Next, the presence and distribution of apo B 100 , sortilin, and GFP in the different subcellular fractions were analyzed by Western blotting (Figure 5B through 5D ). Apo B 100 was present in its native full-length form in the total homogenate and ER fractions and was significantly depleted from the cytosolic fraction. In contrast, the autophagic (containing ) mice (n=3 per group) were injected with a liver-specific adeno-associated vectors (AAV) containing sortilin (AAV-Sortilin) or GFP (AAV-GFP) before isolation of hepatic autophagic vacuoles (see Methods for details). A, Enrichment of the different fractions assessed by Western blotting using the lysosomal marker cathepsin D (mature (mCatD), immature (iCatD), and pro-Cathepsin D (pCatD)), endosomal/lysosomal marker LAMP1 (late endosome and lysosomal marker lysosome-associated protein 1), autophagosome marker LC3 (microtubuleassociated protein light chain 1A/1B-light-chain 3), endosomal marker TfR (transferrin receptor), endoplasmic reticulum (ER) marker ERp72, and cytosolic marker GAPDH. B, Relative distributions of apo B 100 in subcellular fractions. Intact apo B 100 is indicated with an arrow. C, Apo B 100 content in autophagic vacuole fraction (APG) in comparison to homogenate (H) normalized to total protein content. D, Top, Relative distribution of sortilin between AAV-GFP (endogenous) and AAV-Sortilin (overexpressed) injected mice. Because of large differences in expression, representative Western blots show 2 different exposure times. Bottom, GFP relative distribution. E, McA cells (rat hepatoma McArdle RH-7777 cells) transiently transfected using a myc-tagged sortilin plasmid and treated with bafilomycin (100 nmol/L) or vehicle (DMSO) for 3 h. Cells were subjected to a pulse-chase analysis at 2 different chase points, 2 and 4 h (see Methods for details). Myc-sortilin was immunoprecipitated using an anti-Myc antibody, separated by SDS-PAGE and quantified by phosphorimaging. Experiments were performed in duplicate. F, The presence of amphisomes in the APG fraction and of sortilin and apo B 100 in these amphisomes was confirmed by spotting vesicles on a cover slip and staining with indicated antibodies. Single channels, merged images, and insets showing triple colocalization at higher magnification are shown. G-I, Quantification of colocalization of TfR and LC3 to determine amphisome abundance (G), and of apo B 100 (H) and sortilin (I) with indicated markers. Numeric data represents the average±SEM. Statistical analysis performed using 2-tailed t test. *P<0.05 vs 2 h vehicle control. #P<0.05 vs 2 h Bafilo treatment. AUTL indicates autolysosome; C, cytosol; and L, lysosome.
autophagosomes and amphisomes 38 ) and autolysosomal fractions showed an enrichment in full-length and fragmented forms of apo B 100 ( Figure 5B ). If hepatic sortilin overexpression promotes apo B 100 delivery to autophagic vacuoles, we reasoned that with sortilin overexpression, apo B 100 would be enriched in the autophagic fraction relative to the total liver homogenate. Despite not reaching statistical significance (P=0.167, 2-tailed Student t test), all of the mice (n=3 per group) injected with AAV-Sortilin showed increased apo B 100 in the autophagic fraction in comparison to their littermate controls, which were injected with AAV-GFP ( Figure 5C ).
Sortilin was mostly present in the ER and the autophagic fractions, but was depleted in the lysosome and autolysosomal fractions. Like apo B 100 ( Figure 5B), sortilin also underwent fragmentation, but only a single proteolytic band was apparent ( Figure 5D ), which was present in the 3 autophagyrelated fractions (lysosome, autophagic, autolysosomal), but not in ER and total homogenate fractions. For both apo B 100 and sortilin, the fragments are an expected consequence of cathepsin D proteolysis. It is important to note that the relative distribution of sortilin in the livers of AAV-GFP injected mice, in which sortilin is expressed at wild-type levels, is essentially identical to that of sortilin in AAV-Sortilin-injected mice ( Figure 5D ; Online Figure VIB) . Analysis of sortilin's intracellular distribution was alternatively assessed in McA wild-type cells and McA-sortilin cells exposed to vehicle or bafilomycin using confocal microscopy (Online Figure VII) . In the control, sortilin localized near the nucleus, whereas bafilomycin treatment promoted a dispersed distribution of sortilin in both cell types (Online Figure VII) . GFP was only present in mice injected with AAV-GFP and showed the same distribution as other cytosolic proteins (ie, GAPDH, as shown in Figure 5A ), but was also present in the autophagic compartments as a result of bulk cytosolic sequestration ( Figure 5D ; Online Figure VIC) .
Because the sortilin subcellular distribution follows the same pattern as apo B 100 (ie, more abundant in the autophagic than in the autolysosomal fraction; Figure 5B and 5D), we hypothesized that sortilin is also degraded in the lysosome. To test this hypothesis, McA cells were transfected with a plasmid encoding Myc-tagged full-length sortilin, the cells were treated with bafilomycin for 3 hours to inhibit lysosomal degradation, and a pulse-chase analysis was performed. We found that bafilomycin treatment increased sortilin levels in a timedependent manner, suggesting that sortilin is indeed degraded by the lysosome (Figure 5E ). These results are consistent with previous data [39] [40] [41] and are also consistent with the presence of sortilin in autophagic vacuoles that ultimately fuse with the lysosome.
To further establish amphisomes as an intermediate in the pathway of sortilin-mediated apo B 100 degradation, we asked whether endosomal cargo resided in the different isolated compartments. As shown in Figure 5A , we found that TfR (transferrin receptor) was detected in lysosomes-as expected from the delivery of endocytic cargo to lysosomes-but was also present in the autophagic and autolysosomal fractions. This observation suggests either possible endosomal contamination of the fractions or the presence of hybrid autophagosome/endosome components (ie, amphisomes). To distinguish between these possibilities, we spotted vesicles from the autophagic fraction on a glass coverslip and immunostained them with different antibodies. As shown in Figures 5F through 5I , we confirmed that about half of the LC3-positive compartments were also positive for the endosomal marker, transferrin receptor, and that all of the transferrin receptor-positive compartments had LC3 label. Therefore, the double-labeled compartments represent bona fide autophagosomes, but not endosomes. Although 4 color labeling was not possible because of antibody availability, triple labeling confirmed that apo B 100 and sortilin colocalized in ≈75% of these examples and that they both also colocalized with LC3 and transferrin receptor. Overall, these data confirm the presence of both sortilin and apo B 100 in amphisomes.
Increased Sortilin Expression Enhances Autophagic Flux
Sortilin is a critical mediator of lysosomal trafficking and degradation, which suggests that the receptor may also play a more global role in autophagy beyond its role in apoB metabolism. To test this hypothesis, we used primary mouse hepatocytes transduced with an adenovirus encoding the LacZ reporter gene (AV-LacZ, control) or a full-length human sortilin construct (AV-Sortilin). After 24 hours, cells were incubated in the presence of the lysosomal protease inhibitors leupeptin and E64D, or vehicle (water) for 4 hours, and intracellular levels of the autophagosome marker LC3 were determined by immunofluorescence microscopy.
As shown in Figure 6A , whereas no significant differences in LC3 fluorescence levels were observed between untreated AV-LacZ and AV-Sortilin hepatocytes, on treatment with the protease inhibitors, both sets of cells showed an increase in LC3, but the relative increase was significantly greater in the sortilin-overexpressing cells. We next collected total cell lysates to determine changes in LC3-II, which is the form of LC3 associated with autophagic vacuoles that consequently undergo lysosomal degradation. 42 However, we failed to note significant differences in steady-state levels of LC3-II between cells infected with AV-LacZ or AV-Sortilin ( Figure 6B) ; in contrast, treatment with the protease inhibitors increased LC3-II levels in both cell types with a significantly more pronounced effect in sortilin-overexpressing cells ( Figure 6B ). Overall, these results suggest that sortilin overexpression enhances autophagic flux in both transformed and primary hepatic cells.
We also measured p62 protein levels, which usually correlate inversely with autophagic activity, 43 in the total liver homogenate of mice injected with AAV-GFP or AAV-Sortilin (n=6 per group) 2 weeks before analysis. As anticipated, p62 levels in total liver homogenate were reduced in mice injected with AAV-Sortilin, confirming that sortilin overexpression promotes autophagic activity in the liver (Online Figure  VIIIA) .
Apo B 100 Expression Influences Sortilin-Dependent Autophagic Flux
To determine if the stimulatory effect of sortilin on autophagy was related to its ability to increase apo B 100 delivery for autophagy, we studied HUH7 human hepatic cell lines engineered to overexpress sortilin under the control of an inducible February 16, 2018 promoter. 4 These cells harbor the full-length human sortilin gene under the control of a doxycycline-inducible promoter. To assess the differential effect of sortilin on autophagic flux based on apo B 100 abundance, we used siRNA to reduce expression of apo B 100 in these cells.
First, the HUH7 sortilin-expressing cells were treated with scrambled siRNA for 24 hours and then exposed to doxycycline for 48 hours to induce sortilin overexpression. After incubation with protease inhibitors, the cells were harvested and LC3-II levels were measured to determine autophagic flux. Similar to our findings in mouse primary hepatocytes ( Figure 6A and 6B), we observed a significant increase in LC3-II flux (as reflected by LC3-II degradation) in cells where sortilin expression was induced ( Figure 6C ). This sortilininduced increase in LC3-II flux was absent when cells were treated with apo B 100 siRNA ( Figure 6C ). Expression of sortilin in HUH7 cells also increased steady-state levels of LC3-II ( Figure 6C ), but this increase was independent of the level of apo B 100 . The increase in LC3-II flux was attributed neither to doxycycline (Online Figure VIIIB) nor to sortilin overexpression increasing LC3 transcription (Online Figure VIIIC) . Instead, the effect of sortilin overexpression on autophagy is consistent with effects observed on expression of other autophagy receptors, such as optineurin or TRIM30. 44, 45 These results further establish the role of sortilin in the regulation of autophagy and demonstrate that recognition between an autophagy receptor and its cargo can induce this pathway.
The Cytosolic Tail of Sortilin Facilitates Both Apo B 100 Degradation and Enhanced Autophagic Flux
To determine if the sortilin-dependent increase in autophagic flux is related to its role as a mediator of TGN and endocytic trafficking, we studied 2 sortilin mutants that compromise Golgi-to-endosome transport in HUH7 cells. 46 We previously showed that these sortilin mutated forms have no effect on apo B 100 secretion. 4 The LAYA mutant lacks the tyrosine and dileucine sorting motifs located on the cytoplasmic tail. 46 The STOP mutant lacks the entire cytoplasmic tail because of the generation of a premature stop codon ( Figure 7A ). HUH7 sortilin-expressing cells under the control of the doxycyclineinducible promoter were used as controls ( Figure 7B) .
In contrast to the positive effects of sortilin overexpression on autophagy, as described above, expression of the Sortilin STOP or LAYA proteins blocked sortilin-induced autophagic flux ( Figure 7C through 7F) . From these results, along with previous findings, 4 we conclude that these sorting elements are required for sortilin to direct apo B 100 for autophagic degradation and to increase the degradative capacity of the autophagy pathway.
Discussion
Nine years ago, a single-nucleotide polymorphism near the SORT1 locus was discovered by genome-wide association studies to be strongly associated with reduced LDL-C, protection from atherosclerotic cardiovascular disease, and, in minor allele homozygotes, a 12-fold increase in hepatic SORT1 expression. 2 Indeed, our previous studies in mice and hepatic cells established that increased sortilin expression reduces apoB lipoprotein production, which can be reversed in vitro with a lysosomal inhibitor and in vivo by the use of sortilin mutants compromised for lysosomal trafficking. 4 These findings helped explain the genome-wide association studies data and are consistent with sortilin being a member of the Vps10p sorting family, which bind protein cargo in the Golgi for vesicular transport to the endosomal compartment. From here, these cargo molecules are distributed to multiple locations, including the lysosome. 47 Nonetheless, significant gaps remained in our understanding of sortilin's role in apo B 100 and VLDL metabolism.
Two open questions that we have answered in this report are the prior lack of direct evidence showing that increased SORT1 expression promotes apo B 100 degradation, and, assuming that it does, the cellular itinerary taken by apo B 100 during the degradation process. We now show that (1) increased SORT1 expression in hepatic cells decreases recovery of apo B 100 by diverting it from the secretory pathway and promoting its autophagic degradation, and (2) increased expression of sortilin traffics the diverted apo B 100 to autophagic vacuoles through amphisome intermediates, which represent the fusion of endosomes with autophagosomes. Furthermore, our data demonstrate that sortilin is a global regulator of autophagic capacity, a phenomenon that is dependent both on the presence of an embedded region required for its intracellular trafficking and the level of apo B 100 expression. Taken together, these findings provide a novel mechanistic basis for the lower LDL-C in individuals homozygotic for the SORT1 allele associated with increased hepatic expression of sortilin.
Because sortilin begins to interact with cargo in the TGN, our results position degradation of apo B 100 after SORT1 overexpression as another example of post-ER presecretory proteolysis, a phenomenon we initially reported in 2001. 48 One example of post-ER presecretory proteolysis is N-3 fatty acidinduced autophagic degradation of apo B 100 that is damaged by lipid peroxidation. 21 It was not obvious that overexpression of SORT1 would be another example for 2 reasons, one being the differences in the metabolic perturbations. The other is that the conventional understanding of lysosomal targeting by either an M6PR (mannose 6-phosphate receptor)-dependent or M6PR-independent (eg, sortilin) mechanism in what has been termed the direct pathway is that sorting receptors bind and concentrate client proteins in areas of the TGN from which vesicles bud and traffic to the endosomal compartment. This is followed by endosomal maturation and eventual fusion with lysosomes. 49 Thus, there is no requirement for entry into the autophagic machinery during this itinerary. That sortilin and apo B 100 colocalize in amphisomes, structures resulting from the fusion of early or late endosomes and autophagosomes 38 mean that unlike classical transport to lysosomes, apo B 100 targeting is unconventional and indirect.
Our finding that sortilin affects autophagic capacity in a manner dependent on the level of apo B 100 expression is consistent with previous studies on Aβ oligomers, which are linked to the pathogenesis of Alzheimer disease. As recently shown, these oligomers, like apo B 100 , are sortilin ligands and can trigger autophagic flux in cultured neurons; however, preincubation with SORT1 siRNA blocked these effects. 50 Interestingly, both Aβ oligomers and apo B 100 are aggregation prone, 21, 51 implying that sortilin may be especially adept at handling insoluble ligands. Our results are also reminiscent of the increase in autophagy observed on expression of other autophagy receptors, such as optineurin or TRIM30, further supporting the model that recognition between an autophagy receptor and its ligand-cargo is capable of inducing this pathway. 44, 45 On the basis of our data, adjusting the level of autophagy to the level of apo B 100 expression may represent 1 strategy to meet the challenges that this protein presents to hepatic cells. Apo B 100 is a 4536 amino acid protein with extensive hydrophobic patches and multiple intramolecular disulfide bonds. Its folding and assembly into nascent pre-VLDL particles requires processing in the ER, with still more maturation of pre-VLDL occurring in the Golgi to achieve a secretion-competent state. 12, 13 To destroy apo B 100 and thus regulate its levels, autophagy/post-ER presecretory proteolysis can be viewed as a quality or quantity control pathway that serves as a late-stage checkpoint to protect hepatic cells from the accumulation of apo B 100 and VLDL particles that are otherwise too large to be handled by the ER-associated degradation pathway, 52 which requires retrotranslocation from the ER and degradation by the proteasome. Given the inefficiency in ultimately forming mature VLDL particles, the level of apo B 100 expression will have an impact on the abundance of the potentially toxic intermediates, and increasing autophagy can be viewed as a protective, homeostatic response.
Although we have only investigated the role of sortilin in apo B 100 degradation, which involves diverting apo B 100 from the secretory pathway, we recognize that sortilin can also facilitate apo B 100 /VLDL secretion, as revealed in mice deficient in whole body or hepatic sortilin. 4, 7, 9 Because sortilin initially serves to target cargo from the TGN to the endosomal compartment, 47 the subsequent and divergent steps (ultimately to either the lysosome for degradation or the plasma membrane for secretion) are expected to require different mechanisms. Indeed, it has recently become more generally appreciated that specialized vesicles can traffic cargo proteins that, like apo B 100 , have either secretory or degradation fates. 53 Notably, a fraction of such vesicles, dubbed perhaps paradoxically as secretory autophagosomes, fuse with early or late endosomes to form amphisomes so that the ferried cargo is eventually degraded by the lysosome. Further studies, beyond the scope of present report will be required to determine the relationship between this process (secretory autophagy) and the degradation mediated by increased sortilin expression. At a minimum, even if the 2 processes are unique, the involvement of an amphisome intermediate seems to be common and essential. Further studies will also be needed to determine the mechanistic relationships, if any, in the aforementioned phenotypic similarity (decreased apoB and VLDL secretion) in SORT1-overexpressing versus SORT1-deficient mice. Because no individual with SORT1 deficiency has been described, we have exclusively focused in this report on the clinically relevant setting, that is, SORT1 overexpression, and have summarized our present understanding of the cellular relationships between this overexpression and presecretory apo B 100 metabolism in Online Figure IX .
It is also important to place the present findings in the context of other data. Our laboratory and the groups of Janet and Charles Sparks have reported that insulin, a physiological regulator of VLDL production in mammals, promotes the degradation of apo B 100 by autophagy. 54, 55 In subsequent studies, the Sparks have shown that insulin increases the interaction of apo B 100 with sortilin before degradation. 32, 56 On the basis of our data, we suggest that increased sortilin-apo B 100 interaction provides a plausible mechanism for insulininduced apo B 100 autophagy. That sortilin is an important mediator of the effects of insulin on apo B 100 /VLDL metabolism is also supported by work from the Ai et al 5 laboratories in which hepatic sortilin expression was suppressed and VLDL production was increased in insulin-resistant (ob/ob) mice. Notably, these events were reversed when sortilin expression was restored. 5 Another context to place the present findings in is apo B 100 degradation in general. Based on the data in Results, sortilin overexpression explains almost 30% of the autophagic degradation of apo B 100 , consistent with the degree of reduction of apo B 100 in preclinical models ( 4 and the present results). Though this may seem modest, in individuals homozygotic for the SORT1 allele associated with hepatic overexpression, there is a 40% reduction in cardiovascular disease risk. Similar to loss-of-function PCSK9 mutations, 57 this likely represents the clinical benefits of a lifelong mild reduction in LDL-C.
In summary, we have shown that increased hepatic SORT1 expression, to mimic individuals homozygotic for the minor allele, diverts apo B 100 from the secretory pathway to a degradation process that requires autophagy. This indirect route is distinct from the more conventional, direct trafficking route from the TGN to the lysosome. The complexity of this pathway likely evolved to enable sortilin to serve a dual role in lipoprotein metabolism, namely to promote apo B 100 degradation and VLDL secretion, with the impact on each aspect appropriately scaled to metabolic factors. Future studies will undoubtedly uncover other novel mechanistic features of the apo B 100 degradation pathway, some of which may be therapeutically applicable. Nevertheless, the present results significantly extend the mechanistic basis for the decreased LDL-C levels in humans with increased hepatic SORT1 expression.
